Tag Archives: Marc Dunoyer

Transthyretin amyloid cardiomyopathy: Alexion granted an exclusive worldwide licence to develop, manufacture and commercialise NI006 as part of an agreement with Neurimmune AG

Investigational human monoclonal antibody in Phase Ib development for the treatment of transthyretin amyloid cardiomyopathy, a systemic, progressive and fatal condition (PRESS RELEASE) CAMBRIDGE, 7-Jan-2022 — /EuropaWire/ — AstraZeneca (LON: AZN), a British-Swedish multinational pharmaceutical and biotechnology company, has announced … Read the full press release

AL Amyloidosis: Alexion, AstraZeneca Rare Disease, takes over Caelum Biosciences, Inc.

(PRESS RELEASE) CAMBRIDGE, 29-Sep-2021 — /EuropaWire/ — AstraZeneca (LON: AZN), a British-Swedish multinational pharmaceutical and biotechnology company, has announced its rare diseases arm Alexion has exercised its option to acquire all remaining equity in Caelum Biosciences, Inc., a Clinical Stage … Read the full press release